Your browser doesn't support javascript.
loading
Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial.
Wang, Guiqiang; Zhao, Kexin; Han, Jun; Hu, Zhongyu; Zhang, Tianzuo; Wang, Yanchao; Shi, Rui; Li, Yanhua; Song, Qinqin; Du, Haijun; He, Peng; Xu, Shuping; Yang, Xinjie; Fu, Yongpan; Cui, Yimin; Xie, Liangzhi.
Afiliação
  • Wang G; Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital; Department of Infectious Disease, Peking University International Hospital, Beijing, China.
  • Zhao K; Hebei Petro China Central Hospital, Langfang, China.
  • Han J; State Key Laboratory of Infectious, Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Hu Z; National Institutes for Food and Drug Control, Beijing, China.
  • Zhang T; Hebei Petro China Central Hospital, Langfang, China.
  • Wang Y; Hebei Petro China Central Hospital, Langfang, China.
  • Shi R; Hebei Petro China Central Hospital, Langfang, China.
  • Li Y; Hebei Petro China Central Hospital, Langfang, China.
  • Song Q; State Key Laboratory of Infectious, Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Du H; State Key Laboratory of Infectious, Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • He P; National Institutes for Food and Drug Control, Beijing, China.
  • Xu S; Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, China.
  • Yang X; Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, China.
  • Fu Y; Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, China.
  • Cui Y; Department of Pharmacy, Peking University First Hospital; Institute of Clinical Pharmacology, Peking University Beijing, China. Electronic address: cui.pharm@pkufh.com.
  • Xie L; Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, China; Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: LX@sinocelltech.com.
J Infect ; 86(2): 154-225, 2023 02.
Article em En | MEDLINE | ID: mdl-36403700
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: J Infect Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: J Infect Ano de publicação: 2023 Tipo de documento: Article